Answers are grounded in this paper and cite their sources.
Selective oestrogen receptor modulators effectively reduce breast cancer in women at moderate to high risk, so why aren't they being discussed routinely?
No takes yet. Share an insight, caveat, or question.
Harvey et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: